Transcript The Prostate Cancer Symposium

The Prostate Cancer
Symposium
 An Educational Initiative for Patients
and Healthcare Professionals
 October 6, 2009
Concept
 Provide access to information and thought
leaders to promote best standards of care
 dual-track format to maximize interaction
 Provide a faculty of world-class clinicians
and researchers who set the standards of
care
Meeting Objectives
 Patients:
 understand role of biomarkers of diagnosis/progression
 describe current treatments and emerging drug protocols
 discuss the importance of effective patient/doctor
dialogues
 Professionals:





identify best standards of care
Define the impact of treatment on co-morbid conditions
Discuss the advances in therapeutic and drug protocols
Describe the appropriate use of novel therapies
Evaluate the information’s applicability to practice
management
Registered Attendance
 Patients/spouses, Advocates
 Targeted - 300; Actual - 120 (on-site):
 41% Advocates; 32% Patients; 6% Spouses/Partners; 21%
Family/Caregivers
 follow-on distribution - 164:
 29% Advocates; 37% Patients; 18% Spouses/Partners; 16%
Family/Caregivers
 Professionals
 Doctors: Targeted - 100; Actual - 20 (on-site):
 Medoncs - 6
 Radoncs - 2
 Primary Care - 12
 Nurses, Public Health Staff; Industry:
 Targeted - 20; Actual - 17 (on-site)
 follow-on distribution - 38:
 Urologists -7; RadOncs - 3; MedOncs - 9; NP/PAs - 8;
Medical Centers/Public health agencies - 11
Patient Disease Stages
 Primary Therapy:
 Surgery - 42%; Radiation - 27%; Active Surveillance 27%; Drug therapy - 4%
 Disease progression from primary therapy:
 35% - yes; 64% - no; 1% - not sure
 Current Therapy:
 Not currently being treated - 82%
 Hormonal therapy - 8%
 Chemotherapy - 8%
 Complementary/Alternative medicine - 2%
 Previous or current Androgen Deprivation Therapy - 29%
Faculty Comments
 Went well for a first meeting
 Ian Thompson
 Captured a heterogeneous audience
 Natasha Kyprianou
 Develop a “Clinical Trials” program
 Tia Higano; Dan Petrylak
 Offer as a regional format
 Brian Stone (multiple comments)
 Truly excellent conference...great response
from both sides of the aisle
 Andrew Salner
On-going Concerns
 “Lack of educational efforts”
 “Will screening be part of healthcare reform”
 “...men of color MUST take care of themselves”
 “the quality of the faculty was over the top”
 “more time for advanced disease needed”
Listening to the Audience:
ARS initiative
PSA Controversy
 Patient/Professional divergences
 Lack of clear-cut risk communications
 Risk of advanced stage first diagnosis
 Hidden impact on co-morbid conditions
Clinical Trials Dichotomy
 Dialogue Issues
 Need for actionable patient information
Understanding the Barriers
 Need to deliver actionable professional info
 Empower the patient to access trials
Leveraging Awareness
 Heighten drug knowledge for patients and
professionals
Promote Dialogue
 Breaking down the barriers to
communication
The Prostate Net Patient Site
www.theprostatenet.org
Traffic Stats

Traffic since inception September 1996: 5.6 million visits

average 7,528 visits/month; average page views/visit – 5.73

Monthly Traffic 2009 vs. 2008: up 12.3%

Traffic source by category/domain:
 US patient/family – 70.30%
 US commercial organizations - 6.51
 US educational/healthcare/non-profit - 6.39
 US Government/military - 1.41
 Foreign domains - 15.39
Enhancing Awareness
Delivering Information
• Committed Sites for 2010
•May 15 - Rutgers School of Public Administration:
Prostate Cancer Educational Symposium
•June 19 - Lombardi Cancer Center: Town Hall on Prostate
Cancer
•July 17 - Clark Atlanta University Clinical Cancer
Research Center
• August 4 - 7: Prostate Cancer Foundation of Australia:
Prostate Cancer Symposium
•August 28 - University of Florida Prostate Cancer
Symposium
• September 11 - Northwestern (Chicago) Prostate
SPORE: Pca and Community Outreach
• October - The Prostate Net: Prostate Cancer
Symposium
Feedback Mechanisms
 TPN Website archive of Symposium
presentations
 Structured access to information and ARS
 “Survey Monkey” to build information cadre
 Ability to probe for actionable data
 Continuing dissemination/response network
Thank You!
WWW.THEPROSTATENET.ORG
www.youtube.com/user/vhsimons/
www.facebook.com/vhsimons
http://twitter.com/vhsimons
www.linkedin.com/in/virgilsimons/
1.888.477.6763